tbuckley/cabot-search huggingface dataset:
Cough score in patients with different etiology of chronic cough
Authors: Ru-chong Chen, Ke-fang Lai, Wei Luo, Chun-li Liu, Nan-shan Zhong
Journal: BMJ (2008)

Objective To investigate the severity of cough in patients with different etiology of chronic cough and its related factors. Methods One hundred and fifty patients with chronic cough were recruited. The diagnosis of the patients was as follows: 24 cases with post nasal drip syndrome (PNDs), 26 cough variant asthma (CVA), 20 gastroesophageal reflux-induced cough (GERC), 31 eosinophilic bronchitis (EB), 30 atopic cough (AC) and 19 cough post infection (CPI). The severity of cough at daytime and night-time were scored by the doctor and the patient at the first visit. The correlation between cough score and age, gender and course duration of patients was analyzed. Results There was no significantly difference of cough score at daytime among different groups. Cough score at night in CVA group was significantly higher than that of other five groups (all P <0.01). Regression analysis showed that cough score at daytime was significantly correlated with age of patients (P < 0.05), while cough score at night was correlated significantly with gender (P < 0.01). Conclusion Cough severity at daytime in different etiology of chronic cough is similar, while that at night in patient with CVA is higher than that with other etiology.

Key words: 
Cough;  Cough score;  Case-control studies
Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]
Authors: Dong Mei, Binlong Chen, Bing He, Haibin Liu, Zhiqiang Lin, Jialiang Lin, Xiaoyan Zhang, Ning Sun, Libo Zhao, Xiaoling Wang, Qiang Zhang
Journal: Acta Pharmaceutica Sinica B (2020)

[This corrects the article DOI: 10.1016/j.apsb.2019.03.006.].
A multi-center research on risk factors of hyperbilirubinemia in late preterm infants
Authors: Xiaochun Chen, Li Yang, Huihong Zhu, Xin Zhang, Jie Liu, Tongyan Han, Hui Liu, Jü Yan, Zhifang Song, Yabo Mei, Xiaojing Xu, Rong Mi, Xuanguang Qin, Yuhuan Liu, Yujie Qi, Wei Zhang, Huihui Zeng, Hong Cui, Changyan Wang, Zhenghong Li, Hui Long, Guo Guo, Xulin Chen, Zhaoyi Yang, Fang Sun
Journal: BMJ (2018)

Objective
To investigate the risk factors of hyperbilirubinemia in late preterm infants.


Methods
The clinical data of 815 late preterm infants (449 males and 366 females) from 25 hospitals in Beijing were collected from October 2015 to April 2016, including 340 cases(41.7%) with hyperbilirubinemia (hyperbilirubinemia group), and 475 cases without hyperbilirubinemia (control group). The clinical data of two groups were compared, and the maternal factors influencing hyperbilirubinemia in late preterm infants were analyzed with logistic regression.


Results
There were no significant differences in gender ratio (M∶F 1.39 vs. 1.12, t=1.811, P=0.172) and birth weight[ (2 502.6±439.6)g vs. (2 470.2±402.9)g, χ2=2.330, P=0.127) ]between two groups. The incidence rates of hyperbilirubinemia in infants of 34 wks, 35 wks and 36 wks of gestational age were 22.9% (87/174), 35% (119/300) and 42.1% (143/341) respectively (χ2=1.218, P=0.544) . The multivariate logistic regression analysis indicated that the maternal age (OR=1.044, 95% CI:1.010-1.080, P=0.011) was independent risk factor and multiple births (OR=1.365, 95% CI: 0.989-1.883, P=0.048) , premature rupture of membranes (OR=2.350, 95% CI: 1.440-3.833, P=0.001) , cesarean section (OR=1.540, 95% CI: 0.588-4.031, P=0.014) were risk factors for hyperbilirubinemia in late preterm infants.


Conclusions
The incidence of hyperbilirubinemia in late preterm infants is relatively high. Maternal age, multiple births, premature rupture of membranes and cesarean section are risk maternal factors related to hyperbilirubinemia in late preterm infants.


Key words: 
Hyperbilirubinemia; Maternal risk factor; Late preterm infants
Analyses of essential trace elements in 150 maintenance hemodialysis patients' blood
Authors: Xiao-li Han, Wei Zeng, Jie Zhong, Hui Li, Yu-juan Sun
Journal: BMJ (2013)

Atomic absorption spectrometry was employed to determine the levels of 7 essential trace elements in the whole blood of 150 mainteinance hemodialysis (MHD) patients. And comparisons were made with the normal group of 200 participants in routine medical examination at the same time at our hospital. And among 7 indices, as compared with the control group, the blood levels of zinc, chromium, cobalt and manganese were significantly lower (P<0.05) while those of selenium and copper higher (P<0.05). MHD patients lacked essential trace elements to a varying extent. A clinician should pay attention to complementing essential trace elements to improve the patient's quality of life.


Key words: 
Maintenance hemodialysis; Essential trace elements
Serum hepatocyte growth factor and severity of type 2 diabetic nephropathy
Authors: Hong Zhu
Journal: BMJ (2015)

To explore the serum hepatocyte growth factor (HGF) lesion severity level and diabetic nephropathy (DN). A total of 207 patients with type 2 diabetes mellitus (T2DM) were recruited from Second Municipal Hospital. According to the level of urinary albumin excretion rate (UAER), they were divided into non-DN group (group A, n=56): UAER  200 μg/min; DN in clinical renal dysfunction (group D, n=44): UAER >200 μmol/min, decompensated chronic renal failure (serum creatinine: 133-177 μmol/L). And 55 healthy subjects were selected as controls. The serum levels of HGF, fasting plasma glucose , plasma glucose at 2 hour , blood urea nitrogen, creatinine and glycosylated hemoglobin were determined. HGF value: control group: (256.4±30.4) ng/L, group A: (400.1±39.3 )ng/L, group B: (689.4±55.6) ng/L, group C: (967.3±68.5) ng/L and group D: (150.7±23.2) ng/L. There are differences of serum HGF in different degree of DN.


Key words: 
Hepatocyte growth factor; Diabetic nephropathies
常见阴道炎实验诊断方法的应用与评价
Authors: 徐雪松, 金淑杰, 孙志
Journal: BMJ (2006)

阴道炎是育龄妇女的常见病和多发病,患病率较高.最常见的有3种疾病:细菌性阴道病(bacterial vaginosis,BV)、外阴阴道假丝酵母菌病(vulvovaginal Candidiasis,VVC)、滴虫性阴道炎.另外也包括支原体、衣原体性阴道炎,淋菌性阴道炎,尖锐湿疣、生殖器疱疹等性病以及不同病原体混合感染的阴道炎等.阴道分泌物中病原体的检测是确诊阴道炎病因的重要手段,准确、及时的实验室检查具有十分重要的意义。
焦虑症的识别与治疗
Authors: 李春波
Journal: BMJ (2007)

在综合性医院就诊者中,有些患者反复求医,辗转于不同科室或医院.他(她)们对自己的健康过分关注,对身体细微的变化反应敏感,常常根据自己一知半解的医学常识,做出灾难性解释,以致坐卧不安、惶惶不可终日.这类患者可能就是焦虑症患者。
反复发作的嗜酸细胞性十二指肠炎一例
Authors: 陈正言
Journal: BMJ (2008)

患者女,38岁,手套厂工人.因腹痛、腹胀2周,加重2周于2006年3月24日入院.患者2周前开始出现上腹痛,以隐痛为主,同时伴轻度饱胀感,呈间歇性,对生活无大影响,自服胃友等药无效。
麻醉意外纠纷案例分析与应对策略
Authors: 宋咏堂, 罗五金
Journal: BMJ (2004)

因手术而必须进行的麻醉有某些风险,有些风险是灾难性的,甚至是致命性,即麻醉意外.麻醉意外与麻醉行为中的医疗过失有着根本的区别.医疗过失是指医疗机构及其医务人员在医疗活动中,发生违反医疗卫生管理法律、行政法规、部门规章或诊疗护理技术操作规范、常规所导致的不良后果,医疗过失在一定范围内是可以控制和防范的.麻醉意外在麻醉过程中并不违反任何规范或常规,是难以控制和防范的,是麻醉行为本身固有的,具有客观存在性。
The comparative effectiveness of biologic agents among non-hispanic black (NHB) patients with metastatic colorectal cancer (mCRC): Preliminary results of a SEER-medicare analysis.
Authors: Sanjay Goel, Abdissa Negassa, Ana Acuna-Villaorduna
Journal: Journal of Clinical Oncology (2020)

e19059 Background: Biologic agents (bevacizumab, cetuximab, panitumumab) have improved the overall survival (OS) of patients with mCRC. However, clinical trials are plagued by low representation of NHB patients, and a disproportionately high (&gt;90%) accrual of non-Hispanic whites (NHW). As a result, the real world benefit among NHB patients in unknown. Comparative effectiveness research is an approach for effectively addressing this drawback. Methods: Utilizing the SEER-Medicare linked database, we identified 5,728 patients with mCRC diagnosed between 2004 and 2011 who received chemotherapy (CT; oxaliplatin, irinotecan, 5-FU, capecitabine) alone or chemotherapy with a biologic agent (CBT). OS was examined using the Kaplan-Meier method and a weighted semi-parametric accelerated failure time model. A propensity score model approach was undertaken to further account for potential treatment selection bias. Results: Overall, 88% were NHW and 12% NHB patients. The median age at diagnosis was 73 and 70 years and exposure to biologics was 71.2% and 71.4%, respectively. NHB patients had more women, were single, had lower median incomes, better differentiated tumors, less rectal primary cancers, more right sided tumors, and a worse Charleson co morbidity index. There was no difference in the receipt of 1 (72%) vs &gt; 2 (28%) lines of therapy. The median OS was 11 and 12 months (m) in the CT-alone group, and 21 and 22 m in CBT group, among NHW and NHB, respectively. Based on an unadjusted analysis, receipt of biologics, younger age, left sided primary, well/moderate differentiation, being married, more lines of CT, and lower prevalence of co-morbidity were associated with improved OS. We also performed multiple imputations to properly account for the missing data. Among NHW, median OS was 21 vs 11 m in the CBT and CT groups, respectively (effect 1.47, 95% CI 1.36-1.60, p = 0.0000). Among NHB, median OS was 22 vs 12 m in the CBT and CT groups, respectively (effect 1.48, 95% CI 1.23-1.88, p = 0.0000). All comparisons maintained significance when adjusted for multiple comparisons. We found no interaction between biologics and race (p = 0.8743). On subgroup analysis, those patients receiving both classes of biologics (anti EGFR and anti VEGF) had the best outcome. Conclusions: In this cohort of older patients, CBT was associated with longer survival, regardless of race. Clinicians should offer CBT therapy to all patients to maximize their clinical benefit, factoring in clinical variables, but not their race.
口服降糖药联合基础胰岛素的临床应用
Authors: 傅汉菁
Journal: BMJ (2011)

随着糖尿病教育的普及,越来越多的糖尿病患者开始接受胰岛素治疗.作为临床医生,如何合理选择胰岛素的治疗方案?2型糖尿病患者口服多种降糖药血糖控制仍然不达标,如何开始胰岛素治疗?下面通过一门诊病例来说明口服降糖药与基础胰岛素的联合应用。
近端指间关节周围胶原沉积症二例
Authors: 徐胜前, 徐建华, 连莉
Journal: BMJ (2008)

例1 男,14岁.因双手近端指间关节对称性肿胀1年就诊.1年前出现双手近端指间关节肿胀,无疼痛、活动受限,无晨僵,无口干、眼干.查体:双手第2、3、4、5近端指间关节侧面肿胀(图1),不影响关节伸侧及掌侧面,无压痛,无活动受限。
Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC).
Authors: Ethan Barnett, Joseph Schonhoft, Nikolaus D. Schultz, Jerry Lee, Samir Zaidi, Wassim Abida, Taylor Carmichael, Angel E. Dago, David B. Solit, Rick Wenstrup, Howard I. Scher
Journal: Journal of Clinical Oncology (2020)

5531 Background: Genomic studies have shown that up to 25% of prostate cancer tissue specimens harbor alterations in DNA Damage Repair (DDR) genes, which may sensitize the tumor to poly ADP-ribose polymerase inhibitors (PARPi). Trials evaluating PARPi in patients with DDR deficiencies have shown varied response rates and differences regarding which genomic alterations predict for sensitivity to these agents, with the majority of objective responses seen in BRCA2-altered tumors. These results highlight the need to develop biomarker assays which can predict benefit from PARPi therapy. Tissue and cell-free DNA (cfDNA) have been the most utilized sources of tumor material for analysis in this setting, but success rates of obtaining sufficient tumor for analysis from bone are low and detecting tumor-derived copy number variants (CNVs) in cfDNA is challenging. Circulating tumor cells (CTCs) represent an alternate source of genetic information, for which assays are available to isolate and sequence individual cells in a manner that eliminates background noise from stroma and healthy cells, while capturing inter-cellular heterogeneity. Methods: Blood samples, collected from 138 progressing metastatic CRPC patients within 30 days of a pre-treatment biopsy intended for sequencing using MSK-IMPACT, were sent to EPIC Sciences for CTC analysis. Detected CTCs underwent single cell, low pass whole genome sequencing. Prevalence and concordance of BRCA2 copy-loss, regardless of whether single copy or homozygous, was compared in matched tissue and CTC samples. Results: BRCA2 copy-loss was identified in 21% (23/108) and 50% (58/115) of successfully sequenced tissue and CTC samples, respectively. In the 58 patients with CTC-detected BRCA2 loss, BRCA2 loss was detected in 36% (220/565) of the sequenced CTCs, representing a median of 46% (range 4-100%) of CTCs found in each individual sample. When both sequencing assays were successful, BRCA2 loss was detected in CTCs in 84% (16/19) of the tissue-positive cases, whereas tissue sequencing detected BRCA2 loss in 35% (16/46) of CTC-positive cases. Conclusions: Data from this study supports the notion that single-cell CTC sequencing can detect BRCA2 copy-loss at a high frequency, including cases that were negative in tissue, while also characterizing inter-cellular heterogeneity. Further studies will investigate whether CTC BRCA2 copy-loss can predict the likelihood of response to PARPi.
Combined surgeries for retroperitoneal tumors.
Authors: Oleg I. Kit, Oksana V. Katelnitskaya, Andrey A. Maslov, Yuriy A. Gevorkyan, Evgeniy N. Kolesnikov, Vladimir S. Trifanov, Mikhail A Kozhushko, Irina B. Lysenko
Journal: Journal of Clinical Oncology (2020)

e23579 Background: Retroperitoneal tumors are rare heterogeneous malignant tumors. Due to their poor response to chemoradiotherapy, surgery is the main treatment option. Currently, there is little data on treatment outcomes in patients who underwent en block resection of retroperitoneal tumors and major vessels. Our purpose was to analyze surgical and oncological results in patients with retroperitoneal tumors and major blood vessel involvement. Methods: 27 patients received surgery for retroperitoneal tumors with major vessel resection in 2015-2019. Results: The mean tumor diameter was 17 cm (11-39 cm). The most frequent histological types were moderately differentiated liposarcoma (33.4%), well differentiated (18.5%), poorly differentiated sarcoma (18.5%), pleomorphic liposarcoma (22.2%), leiomyosarcoma (7.4%). Resection of the suprarenal inferior vena cava (IVC) with prosthetics was performed in 4 cases, resection of its renal segment with renal vein reimplantation - 1, resection of the infrarenal IVC with prosthetics - 8. PTFE prostheses were used as a conduit in all cases. Marginal excision of the suprarenal IVC was performed in one patient, that of the infrarenal IVC - in 5 patients; resection of the infrarenal IVC without the reconstruction - in one case. The iliac venous segment resection was required in 6 patients, in one case – with the iliac arterial segment resection and prosthetics. Macroscopic complete resection (R0-R1) was achieved in 92.6%. The postoperative morbidity was 25.9%, with no fatal outcomes. Despite the anticoagulant therapy, the frequency of thrombosis of the venous reconstruction area in the early postoperative period (1 month) was 7.4%. The median relapse-free survival was 14 months; the median overall survival was not achieved. Conclusions: Combined surgeries with simultaneous removal of retroperitoneal tumor and angioplasty demonstrate an acceptable level of morbidity and mortality. Radical removal of tumors with major blood vessel involvement allows increasing the survival in patients often considered inoperable.
Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US).
Authors: Xuehua Ke, Marie-Hélène Lafeuille, Hela Romdhani, Frederic Kinkead, Peter St. John Francis, Denise D'Andrea, Charles J. Ryan, Stephen J. Freedland
Journal: Journal of Clinical Oncology (2020)

e19138 Background: mCSPC is clinically complex. Although consensus on treatments are evolving, ADT remains the backbone of therapy. This study assessed the proportion of mCSPC patients treated with ADT only or remaining untreated and their HRU during the mCSPC period in the US. Methods: The Optum Clinformatics Extended DataMart was used to identify men with ≥2 claims for prostate cancer (PC), ≥1 claim for metastasis, ≥1 castration sensitivity (CS) indicator (CS diagnosis code [dx]; castration and no prostate-specific antigen [PSA] rise; or hormone/castration naive for ≥18 months [mo] before index [date of 1 st metastasis dx on or after 1 st PC dx and between 2015-2018]). Patients were excluded if they had a pre-index castration-resistance (CR) indicator (CR dx; castration within ≥90 days pre-index or with PSA rise; or a claim for a drug solely recommended for metastatic CRPC). mCSPC period (F/U) was defined as time from index until CR (i.e., any post-index CR indicator or initiation of abiraterone acetate or docetaxel ≥12 mo after post-index ADT initiation or ≥12 mo post-index for those with no ADT) or end of data. The proportion of patients receiving ADT only or no mCSPC treatment during F/U was reported. Per-patient-per-year (PPPY) all-cause HRU were evaluated during baseline (12 mo pre-index) and F/U. Descriptive statistics were used: n (%) for binary and mean [SD] for continuous variables. Results: A total of 2,825 mCSPC patients were identified (age: 75 [9] years). Of these, 2,181 (77%) received ADT only or no treatment in a F/U of 10.9 [9.0] mo. Among them, there were more patients with ≥1 inpatient (IP) stay or ≥1 emergency room (ER) visit (F/U vs. baseline; IP: 50% vs. 20%; ER: 57% vs. 44%), and patients had more IP stays and ER visits (IP: 2.0 [4.0] vs. 0.3 [0.7] stays; ER: 3.2 [7.1] vs. 1.1 [2.2] visits) and more IP days (27 [61] vs. 3 [11] days) PPPY in F/U vs. baseline. Trends were similar among patients receiving ADT only (N=1,252 [44%]; F/U of 12.6 [9.0] mo; Table). Conclusions: The majority of mCSPC patients were treated with ADT only or remained untreated and incurred substantial HRU. These findings suggest that improvements in therapy and prompt treatment initiation in men with mCSPC are needed to improve outcomes. [Table: see text]
尿激酶序贯曲安奈德胸腔注射治疗结核性包裹性胸腔积液
Authors: 张凤英, 杨淑梅, 安玉强
Journal: BMJ (2007)

将60例结核性包裹性胸腔积液的住院患者以随机抽签法分为观察组(A)和对照组(B),两组抽净积液后,包裹腔内注入尿激酶,连续注射2 d后,B组每周抽水2次,A组隔日抽水后注入醋酸曲安奈德.结果显示,A组治愈率、近期胸膜肥厚发生率分别为93.3%(28例)和13.3%(4例),明显优于B组治愈率的70.0%(21例)和近期胸膜肥厚发生率83.3%(25例)。
Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.
Authors: Alessandro Santin, Takefumi Komiya, David M. Goldenberg, Robert M. Sharkey, Quan Hong, William A. Wegener, Trishna Goswami, Aditya Bardia
Journal: Journal of Clinical Oncology (2020)

6081 Background: Unselected pts with EC who progressed on prior chemotherapy have a poor prognosis with limited treatment options. SG is a novel antibody-drug conjugate that targets Trop-2, a cell surface glycoprotein highly expressed in many epithelial tumors. It is conjugated to deliver SN-38, the active metabolite of irinotecan, via a proprietary hydrolyzable linker. Preclinical studies show SG has activity against chemotherapy-resistant EC and significant bystander effect against EC with heterogenous Trop-2 expression (Perrone E. Mol Oncol. 2019). Methods: The phase I/II basket study (NCT01631552) evaluated pts unselected for Trop-2 with advanced solid tumors who received intravenous SG (days 1 and 8 of 21-day cycles), until progression or unacceptable toxicity. CT/MRI scans were obtained at 8-week intervals for response assessment by RECIST 1.1. We report results for mEC pts who progressed after ≥1 prior systemic therapy and were treated with SG 10 mg/kg. Endpoints include safety, objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Results: 18 mEC pts (all women; 17 white and 1 black; median age 69 years [range, 41–76]) had a median 3.5 (range 2–6) prior lines of therapy. All pts received prior treatment with platinum therapies. At a median follow-up of 12.7 months, the ORR (95% CI) was 22.2% (6.4–47.6), with 4 partial responses. CBR (95% CI) was 44.4% (21.5–69.2), with 8 of 18 pts having either an objective response or stable disease ≥6 months. The DOR of responders ranged from 9.1 to 26.6 months, with 2 of 4 responders having a duration of ≥18 months. Median PFS (95% CI) was 3.2 months (1.9–9.4), and median OS (95% CI) was 11.9 months (4.7–not calculable). Key grade ≥3 TRAEs in the overall basket study safety population (n=495) included neutropenia (28%), neutrophil count decrease (14%), anemia (10%), diarrhea (8%), fatigue (6%), and febrile neutropenia (5%). A similar safety profile was seen in the mEC cohort. Conclusions: Median OS in unselected pts with mEC who progressed on prior platinum therapy is ~10 months with an ORR of ~10%. SG monotherapy showed clinical activity in pts with relapsed/refractory mEC, consistent with previous preclinical findings, and support further clinical investigation (NCT04251416). The phase II TROPiCS-03 (NCT03964727) study in pts with metastatic solid tumors selected based on elevated Trop-2 expression by a validated IHC assay will also provide further insights. Clinical trial information: NCT01631552.
Low dose ionizing radiation and the injury of germ cells
Authors: 张慧娟, 李亚军, 宋学茹
Journal: BMJ (2011)

能够直接引起介质电离或通过次级过程引起电离的辐射统称为电离辐射,电离辐射主要包括天然电离辐射和人工电离辐射.随着现代医学的发展,电离辐射已广泛应用于医疗行业.电离辐射可引起放射病,它是机体的伞身性反应,几乎所有器官、系统均发生病理改变,但人体中的眼晶体、性腺、乳腺和甲状腺对射线尤其敏感.电离辐射诱导生殖细胞凋亡、细胞周期停滞和DNA破坏,并产生三种自由基导致衰老的发生[1].现实生活中,人们受到大剂量辐射损伤的几率很小,而随着环境中产生低剂量的电离辐射源越来越多,其对人类健康,尤其是对生殖系统的影响不容忽视。
Effects of community education on quality of life in mild-to-moderate chronic obstructive pulmonary disease
Authors: Cai-xia Wang, Xian-qiao Jin, De-rong Peng, Wei-zhen Shen, Wei Shen, Zhong-min Xu, Ping Li
Journal: BMJ (2013)

From January to December 2010, collective, individual and telephone instructions were conducted for one-year health education, exercise therapy, psycho-social and behavioral interventions among 160 patients with mild-to-moderate chronic obstructive pulmonary disease at community health service centers. And another 160 patients were selected for the control group. At 1 year post-intervention, lung function and body mass index improved in both groups. And the intergroup difference was statistically significant (P<0.05). As compared with the control group, the integral average annual number of symptomatic episodes of cough, sputum & dyspnea, number of hospitalizations and duration of stay improved significantly. And the differences were statistically significant (P<0.01).


Key words: 
Community-based health care; Lung disease, chronic obstructive
Survey on management and service needs among elderly dementia patients in Beijing Yuetan community
Authors: Lili Bian, Wuzi Hou, Yuming Dong, Xueping Du, Bin Xu, Jing Ding
Journal: BMJ (2018)

Patients aged ≥65 years with dementia diagnosed by neurological specialists were selected in Yuetan community from March 2016 to December 2016. The basic information of patients was collected from the health and medical records; the needs for community care were obtained through a questionnaire survey. Total 91 elderly patients with dementia was included in the study, among whom 15 (16.5%) were found by community institutions, 18 (19.9%) patients got medication from the community health institutions. The survey showed that the numbers of participants who agreed that the community health service could provide treatment, drug prescription, referral service, condition assessment, regular follow-up, professional guidance for caregivers, door-to-door service and counseling services for patients and their relatives were 29 (31.8%), 18 (19.9%), 33 (36.3%), 19 (20.9%), 23 (25.3%), 24 (26.4%), 49 (53.8%) and 29 (31.9%), respectively. Results showed that 53.8% (49/91) dementia patients or their family members wanted to receive instruction of drug use in community health service, 17.6%(16/91) wanted to know about the professional care skill as caregivers. Currently the services for dementia patients in health service centers and stations of Yuetan community are less sufficient, which cannot meet the needs of dementia patients and their family members.


Key words: 
Dementia; Disease management; Community health services